Samsara Biocapital

,

Website: samsaracap.com

Firm Size

• Assets Under Management (AUM):$1.7 Billion
• Number of Funds:3
• Employees:26
• Firm Type:Venture Capital
• Focus Areas: Software & Technology
  Healthcare
  

Description

Samsara BioCapital, LLC is a venture capital firm focused on investing in companies in the life sciences sector. The firm was founded in 2016 and is headquartered in San Francisco, California. Samsara BioCapital primarily invests in companies involved in pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. The firm aims to support transformative innovations that have the potential to improve patient outcomes and advance medical research. They provide capital, expertise, and strategic guidance to help their portfolio companies succeed. Samsara BioCapital values long-term partnerships with the companies they invest in and actively seeks opportunities to collaborate with them. The investment team at Samsara BioCapital has a deep understanding of the life sciences industry and leverages their scientific, operational, and investment expertise to identify promising investment opportunities. They take a data-driven and rigorous approach to evaluate potential investments, considering factors such as market potential, competitive landscape, technology differentiation, and management team strength. Some of Samsara BioCapital's notable investments include companies working on cutting-edge therapies, including gene therapies, cell therapies, and precision medicine. They have also invested in companies developing novel diagnostic tools and digital health solutions. Overall, Samsara BioCapital, LLC is a venture capital firm that specializes in investing in transformative life sciences companies. They aim to support innovative solutions that have the potential to significantly impact patient care and advance scientific research.

Latest News

Powered by

May 13, 2024: Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024 .

Jul 10, 2023: SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases